Celestica Announces Approval To Proceed With Share Reclassification

Celestica Inc. ((NYSE, TSX:CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today announced, in accordance with the requirements of the Toronto Stock Exchange,

Celestica Inc. ((NYSE, TSX:CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced, in accordance with the requirements of the Toronto Stock Exchange, that the nominees listed in its management information circular were elected as directors of the company at its Annual and Special Meeting of Shareholders held earlier today.

 

On a vote by ballot, each of the following nine nominees proposed by management was elected as a director of Celestica:

Nominee Votes For % Votes For Votes Withheld % Votes Withheld
Kulvinder (Kelly) Ahuja 83,255,455 99.19% 676,581 0.81%    
Robert A. Cascella 79,234,911 94.40% 4,697,125 5.60%    
Deepak Chopra 82,921,882 98.80% 1,010,154 1.20%    
Françoise Colpron 83,017,909 98.91% 914,127 1.09%    
Jill Kale 83,125,894 99.04% 806,142 0.96%    
Laurette T. Koellner 77,101,548 91.86% 6,830,487 8.14%    
Robert A. Mionis 83,851,612 99.90% 80,423 0.10%    
Luis A. Müller 82,909,580 98.78% 1,022,456 1.22%    
Michael M. Wilson 81,673,082 97.31% 2,258,954 2.69%    

Celestica also announced that the resolution regarding the articles of amendment removing provisions concerning Celestica’s multiple voting shares and redesignating Celestica’s subordinate voting shares as common shares was approved at the Annual and Special Meeting of Shareholders. Celestica will be proceeding with the removal of the multiple voting shares and with the reclassification of the subordinate voting shares to common shares.

Total
0
Shares
Related Posts
Read More

Kodiak Sciences Data At ARVO 2024 Highlight Depth Of Early And Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built On Kodiak’s Antibody Biopolymer Conjugate Platform

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple

KOD

Read More

Over $1M Bet On This Tech Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by around 190 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

GROV